Indication:Multiple myeloma (Relapsed)
NICE is unable to make a recommendation about the use in the NHS of bortezomib for treating multiple myeloma after second or subsequent relapse because no evidence submission was received from Janssen-Cilag
Myeloma: diagnosis and management
Full document available at:http://www.nice.org.uk/guidance/ng35/resources/myeloma-diagnosis-and-management-1837394042821
Bortezomib is recommended as an option within its marketing authorisation, that is, in combination with dexamethasone, or with dexamethasone and thalidomide, for the induction treatment of adults with previously untreated multiple myeloma, who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
NICE Guidance TA 228
Bortezomib in combination with an alkylating agent and a corticosteroid is recommended as an option for the first-line treatment of multiple myeloma if:
* high-dose chemotherapy with stem cell transplantation is considered inappropriate
* the person is unable to tolerate or has contraindications to thalidomide.
NICE TA 228 Bortezomib and thalidomide for the first-line treatment of multiple myeloma July 2011